Impact of Body Mass Index and Obesity on Clinical Response to Systemic Treatment for Psoriasis: Evidence from the Psocare Project

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Yearbook of Dermatology and Dermatologic Surgery

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/S0093-3619(08)79286-4
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Impact of Body Mass Index and Obesity on Clinical Response to Systemic Treatment for Psoriasis

  2008cited by this paper

• The obesity–inflammation axis in psoriatic disease: mechanisms and therapeutic strategies

  2025cites this paper
• Eating Disorder Risk Factors and the Impact of Obesity in Patients With Psoriasis.

  2024cites this paper
• Demographics, Disease Characteristics, and Time to Effective Treatment of Patients with Psoriasis in the Ghent PsoPlus Cohort of 2021

  2024cites this paper
• The Link Between Weight-Adjusted-Waist Index and Psoriasis in Adults: A Cross-Sectional Study Based on 2009-2014 and 2003-2006 Data

  2024cites this paper
• Successful long‐term guselkumab treatment of severe plaque psoriasis in patients with class III obesity: A case series

  2023cites this paper
• A value‐based healthcare model for initiating and switching psoriasis therapies—Results from the prospective multicentre IMPROVE study

  2023cites this paper
• Understanding Barriers Impacting upon Patient Wellbeing: A Nationwide Italian Survey and Expert Opinion of Dermatologists Treating Patients with Moderate-to-Severe Psoriasis

  2023cites this paper
• Brodalumab for the Treatment of Moderate-to-Severe Psoriasis: An Expert Delphi Consensus Statement

  2023cites this paper
• Izokibep for the treatment of moderate-to-severe plaque psoriasis: a phase II, randomized, placebo-controlled, double-blind, dose-finding multicentre study including long-term treatment.

  2023cites this paper
• Nail psoriasis dynamics during biologic treatment and withdrawal in patients with psoriasis who may be at high risk of developing psoriatic arthritis: a post hoc analysis of the VOYAGE 2 randomized trial

  2023cites this paper
• Secukinumab dosing every 2 weeks demonstrated superior efficacy compared with dosing every 4 weeks in patients with psoriasis weighing 90 kg or more: results of a randomized controlled trial *

  2022cites this paper
• Response to fumaric acid esters for plaque type psoriasis in real-world practice is largely independent of patient characteristics at baseline – a multivariable regression analysis from the German Psoriasis Registry PsoBest

  2022cites this paper
• Safety, efficacy, and drug survival of the infliximab biosimilar CT‐P13 in post‐marketing surveillance of Japanese patients with psoriasis

  2022cites this paper
• Characteristics of New Biologic Users Among the Moderate-to-Severe Psoriasis Population—Retrospective Cohort Study Leveraging the Modernizing Medicine Data Services Database

  2022cites this paper
• Efficacy of Risankizumab versus Secukinumab in Patients with Moderate-to-Severe Psoriasis: Subgroup Analysis from the IMMerge Study

  2022cites this paper
• Impact of Body Mass Index on the Efficacy of Biological Therapies in Patients with Psoriasis: A Real-World Study

  2021cites this paper
• First-Line Biologic Therapy and Obesity in Moderate-to-Severe Psoriasis: Results from the Prospective Multicenter Cohort Psobioteq

  2021cites this paper
• The Impact of Smoking on Psoriasis Patients with Biological Therapies in a Bucharest Hospital

  2021cites this paper
• Real‐world effectiveness of guselkumab in patients with psoriasis: Health‐related quality of life and efficacy data from the noninterventional, prospective, German multicenter PERSIST trial

  2021cites this paper
• Systematic review and meta‐analysis on prevalence of metabolic syndrome in psoriatic arthritis, rheumatoid arthritis and psoriasis

  2021cites this paper
• Use of brodalumab for the treatment of chronic plaque psoriasis: a one-year real-life study in the Lazio region, Italy

  2021cites this paper
• Psoriasis and Nutritional Therapy

  2021cites this paper
• Certolizumab Pegol in Japanese Patients with Moderate to Severe Plaque Psoriasis: Effect of Demographics and Baseline Disease Characteristics on Efficacy

  2021cites this paper
• The Effect of Antioxidant and Anti-Inflammatory Capacity of Diet on Psoriasis and Psoriatic Arthritis Phenotype: Nutrition as Therapeutic Tool?

  2021cites this paper
• Psoriasis and Nutrition: a focus on Microbiome and Microbiota. A Review

  2021cites this paper
• Improved therapeutic response to biologic treatment after bariatric surgery: Experience from an obese patient with psoriasis

  2020cites this paper
• Раннее назначение генно-инженерных биологических препаратов при иммуновоспалительных заболеваниях: возможности и перспективы. Позиция экспертов

  2020cites this paper
• Efficacy and Safety of Biologics for Psoriasis and Psoriatic Arthritis and Their Impact on Comorbidities: A Literature Review

  2020cites this paper
• The influence of body weight of patients with chronic plaque psoriasis on biological treatment response

  2020cites this paper
• Early prescription of biological agents for immune-mediated inflammatory diseases: opportunities and prospects. An expert’s opinion

  2020cites this paper
• The Role of Leptin in the Association between Obesity and Psoriasis

  2020cites this paper
• Methotrexate and Adalimumab Decrease the Serum Levels of Cardiovascular Disease Biomarkers (VCAM-1 and E-Selectin) in Plaque Psoriasis

  2020cites this paper
• Use of Guselkumab for the Treatment of Moderate-to-Severe Plaque Psoriasis: A 1 Year Real-Life Study

  2020cites this paper
• Psoriasis: Epidemiology, Potential Triggers, Disease Course

  2020cites this paper
• Incentives for Danish healthcare management based on a pilot outcome-based, patient-centric management model in psoriasis and psoriatic arthritis: the non-interventional IMPROVE study

  2020cites this paper
• The pharmacological management of patients with comorbid psoriasis and obesity

  2019cites this paper
• Smoking does not Alter the Therapy Response to Systemic Anti-psoriatic Therapies: A Two-country, Multi-centre, Prospective, Non-interventional Study.

  2019cites this paper
• Pioneers in dermatology and venereology: an interview with Prof. Alberto Giannetti

  2019cites this paper
• Evaluation of Body Composition in Patients with Psoriasis

  2019cites this paper
• Review of European registries for psoriasis

  2018cites this paper
• Subcutaneous methotrexate in patients with moderate‐to‐severe psoriasis: a critical appraisal

  2018cites this paper
• Obesity and response to anti-tumor necrosis factor-α agents in patients with select immune-mediated inflammatory diseases: A systematic review and meta-analysis

  2018cites this paper
• Efficacy of guselkumab in subpopulations of patients with moderate‐to‐severe plaque psoriasis: a pooled analysis of the phase III VOYAGE 1 and VOYAGE 2 studies

  2018cites this paper
• Psoriasis improvement after gastric bandage in a patient partial responder to infliximab

  2018cites this paper
• Baseline patients’ characteristics as predictors for therapeutic survival and response in patients with psoriasis on biological treatments

  2018cites this paper
• Una prospettiva per i registri nella sorveglianza post-marketing dei farmaci

  2018cites this paper
• Treatment Approaches to Moderate to Severe Psoriasis

  2017cites this paper
• Compounds of psoriasis with obesity and overweight.

  2017cites this paper
• Clinical factors predicting the therapeutic response to ustekinumab in patients with moderate to severe chronic plaque psoriasis

  2017cites this paper
• Bioelectrical impedance analysis to define an excess of body fat: evaluation in patients with psoriasis

  2017cites this paper
• Risk of periodontitis in patients with psoriasis and psoriatic arthritis

  2017cites this paper
• Calcipotriol Plus Betamethasone Dipropionate Aerosol Foam in Patients with Moderate-to-Severe Psoriasis: Sub-Group Analysis of the PSO-ABLE Study

  2017cites this paper
• Serum Leptin, Resistin, and Adiponectin Concentrations in Psoriasis: A Meta-Analysis of Observational Studies

  2017cites this paper
• Italian guidelines on the systemic treatments of moderate‐to‐severe plaque psoriasis

  2017cites this paper
• Comorbidities in psoriasis : The recognition of psoriasis as a systemic disease and current management

  2017cites this paper
• The effect of Helicobacter pylori eradication on psoriasis course

  2017cites this paper
• Recent understanding of the etiopathogenesis of psoriasis

  2017cites this paper
• Comorbidities in psoriasis: The recognition of psoriasis as a systemic disease and current management

  2017cites this paper
• Calcipotriol Plus Betamethasone Dipropionate Aerosol Foam is Effective, Independent of Body Mass Index and the Extent and Severity of Psoriasis

  2016cites this paper
• Value in Psoriasis Care: From Patients to Payers

  2016cites this paper
• Inclusion and exclusion criteria in phase III trials with systemic agents in psoriasis: the external validity of drug development

  2016cites this paper
• Body mass index predicts discontinuation due to ineffectiveness and female sex predicts discontinuation due to side‐effects in patients with psoriasis treated with adalimumab, etanercept or ustekinumab in daily practice: a prospective, comparative, long‐term drug‐survival study from the BioCAPTURE r

  2016cites this paper
• Systemic inflammation and proinflammatory interleukin‐17 signalling persist at the end of therapy in patients with metabolic syndrome and psoriasis, reducing the length of remission

  2016cites this paper
• Clinical predictors of nonresponse to anti‐TNF‐α agents in psoriatic patients: A retrospective study

  2016cites this paper
• Psoriasis registries worldwide: systematic overview on registry publications

  2016cites this paper
• The triad psoriasis–obesity–adipokine profile

  2016cites this paper
• Metabolic syndrome and psoriasis severity in South‐East Asian patients: An investigation of potential association using current and chronological assessments

  2016cites this paper
• Prevalence of metabolic syndrome in Montenegrin patients with psoriasis.

  2016cites this paper
• Evidence-based Recommendations for the Management of Comorbidities in Rheumatoid Arthritis, Psoriasis, and Psoriatic Arthritis: Expert Opinion of the Canadian Dermatology-Rheumatology Comorbidity Initiative

  2015cites this paper
• Analysis of Gender Differences in the Efficacy of Psoriasis Treatment Modalities Resulting in Clearance

  2015cites this paper
• Algorithm for Selecting Ideal Biologic Treatment for Psoriasis

  2015cites this paper
• Vitiligo assessment methods – Vitiligo Area Scoring Index and Vitiligo European Task Force assessment

  2015cites this paper
• Differential Drug Survival of Biologic Therapies for the Treatment of Psoriasis: A Prospective Observational Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR).

  2015cites this paper
• Factors associated with the prescription of “traditional” or “biological” systemic treatment in psoriasis

  2015cites this paper
• Lifestyle changes can make a difference in psoriasis

  2015cites this paper
• Effect of lifestyle weight loss intervention on disease severity in patients with psoriasis: a systematic review and meta-analysis

  2015cites this paper
• Genetic Epidemiology of Psoriasis

  2014cites this paper
• Impact of obesity on the effectiveness of adalimumab for the treatment of psoriasis: a retrospective study of 30 patients in daily practice

  2014cites this paper
• Diet and psoriasis, part I: Impact of weight loss interventions.

  2014cites this paper
• Anti-TNF Agents as Therapeutic Choice in Immune-Mediated Inflammatory Diseases: Focus on Adalimumab

  2014cites this paper
• Some clinical factors affecting quality of the response to ustekinumab for psoriasis

  2014cites this paper
• Factors affecting response to biologic treatment in psoriasis

  2014cites this paper
• Long‐term study of infliximab for psoriasis in daily practice: drug survival depends on combined treatment, obesity and infusion reactions

  2014cites this paper
• Clinical predictors of non-response to any tumor necrosis factor (TNF) blockers: a retrospective study

  2014cites this paper
• Body mass index in patients with moderate‐to‐severe psoriasis in Spain and its impact as an independent risk factor for therapy withdrawal: results of the Biobadaderm Registry

  2014cites this paper
• Diet and physical exercise in psoriasis: a randomized controlled trial

  2014cites this paper
• Epidemiology and treatment of psoriasis: a Chinese perspective

  2014cites this paper
• Retention rate of systemic drugs in patients with chronic plaque psoriasis

  2013cites this paper
• Serum chemerin is increased in patients with chronic plaque psoriasis and normalizes following treatment with infliximab

  2013cites this paper
• Glucagon‐like peptide‐1 analogue therapy for psoriasis patients with obesity and type 2 diabetes: a prospective cohort study

  2013cites this paper
• Factors Associated with the Length of Remission of Psoriasis Vulgaris

  2013cites this paper
• Cardiovascular aspects of psoriasis: an updated review

  2013cites this paper
• Management of systemic treatment of moderate-to-severe psoriasis : brief literature review with reference to the most relevant Italian experiences

  2013cites this paper
• Does weight-adjusted anti-tumour necrosis factor treatment favour obese patients with Crohn’s disease?

  2013cites this paper
• Body weight increment in patients treated with infliximab for plaque psoriasis

  2013cites this paper
• Serum adipokines in patients with psoriatic arthritis and psoriasis alone and their correlation with disease activity

  2012cites this paper
• [Multiplatform application to determine presence of metabolic syndrome and cardiovascular risk in patients with psoriasis].

  2012cites this paper
• Weight Reduction Alone May Not Be Sufficient to Maintain Disease Remission in Obese Patients with Psoriasis: A Randomized, Investigator-Blinded Study

  2012cites this paper
• Efficacy and Safety of Clinical Use of Etanercept for the Treatment of Moderate-to-Severe Psoriasis in Spain: Results of a Multicentric Prospective Study at 12 Months Follow-Up

  2012cites this paper
• Impact of body mass index on retention rates of anti-TNF-alfa drugs in daily practice for psoriasis

  2012cites this paper